{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:22:29Z","timestamp":1777386149517,"version":"3.51.4"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T00:00:00Z","timestamp":1444780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T00:00:00Z","timestamp":1444780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Alzheimer Forschungs Initiative","award":["14801"],"award-info":[{"award-number":["14801"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s00401-015-1489-x","type":"journal-article","created":{"date-parts":[[2015,10,14]],"date-time":"2015-10-14T04:34:00Z","timestamp":1444797240000},"page":"713-729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models"],"prefix":"10.1007","volume":"130","author":[{"given":"Yvonne","family":"Bouter","sequence":"first","affiliation":[]},{"given":"Jose Socrates Lopez","family":"Noguerola","sequence":"additional","affiliation":[]},{"given":"Petra","family":"Tucholla","sequence":"additional","affiliation":[]},{"given":"Gabriela A. N.","family":"Crespi","sequence":"additional","affiliation":[]},{"given":"Michael W.","family":"Parker","sequence":"additional","affiliation":[]},{"given":"Jens","family":"Wiltfang","sequence":"additional","affiliation":[]},{"given":"Luke A.","family":"Miles","sequence":"additional","affiliation":[]},{"given":"Thomas A.","family":"Bayer","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2015,10,14]]},"reference":[{"key":"1489_CR1","unstructured":"https:\/\/clinicaltrials.gov. Accessed 1 July 2015"},{"issue":"28","key":"1489_CR2","doi-asserted-by":"publisher","first-page":"9677","DOI":"10.1523\/JNEUROSCI.4742-11.2012","volume":"32","author":"O Adolfsson","year":"2012","unstructured":"Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, Maloney J, Chen M, Gogineni A, Weimer RM, Mortensen DL, Friesenhahn M, Ho C, Paul R, Pfeifer A, Muhs A, Watts RJ (2012) An effector-reduced anti-\u03b2-amyloid (A\u03b2) antibody with unique a\u03b2 binding properties promotes neuroprotection and glial engulfment of A\u03b2. J Neurosci 32(28):9677\u20139689. doi:10.1523\/JNEUROSCI.4742-11.2012","journal-title":"J Neurosci"},{"issue":"36","key":"1489_CR3","doi-asserted-by":"publisher","first-page":"12790","DOI":"10.1523\/JNEUROSCI.1794-11.2011","volume":"31","author":"A Alexandru","year":"2011","unstructured":"Alexandru A, Jagla W, Graubner S, Becker A, B\u00e4uscher C, Kohlmann S, Sedlmeier R, Raber KA, Cynis H, R\u00f6nicke R, Reymann KG, Petrasch-Parwez E, Hartlage-R\u00fcbsamen M, Waniek A, Rossner S, Schilling S, Osmand AP, Demuth H, von H\u00f6rsten S (2011) Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated A\u03b2 is induced by pyroglutamate-A\u03b2 formation. J Neurosci 31(36):12790\u201312801. doi:10.1523\/JNEUROSCI.1794-11.2011","journal-title":"J Neurosci"},{"issue":"1","key":"1489_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/2051-5960-1-56","volume":"1","author":"G Antonios","year":"2013","unstructured":"Antonios G, Saiepour N, Bouter Y, Richard BC, Paetau A, Verkkoniemi-Ahola A, Lannfelt L, Ingelsson M, Kovacs GG, Pillot T, Wirths O, Bayer TA (2013) N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody. Acta Neuropathol Commun 1(1):56. doi:10.1186\/2051-5960-1-56","journal-title":"Acta Neuropathol Commun"},{"issue":"8","key":"1489_CR5","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6(8):916\u2013919. doi:10.1038\/78682","journal-title":"Nat Med"},{"key":"1489_CR6","unstructured":"Basi G, Jacobsen JS (2009) Humanized antibodies that recognize beta amyloid peptide. Google Patents. http:\/\/www.google.com\/patents\/US7625560"},{"key":"1489_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-014-1287-x","author":"TA Bayer","year":"2014","unstructured":"Bayer TA, Wirths O (2014) Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer\u2019s disease. Acta Neuropathol. doi:10.1007\/s00401-014-1287-x","journal-title":"Acta Neuropathol"},{"issue":"3","key":"1489_CR8","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nn.3028","volume":"15","author":"I Benilova","year":"2012","unstructured":"Benilova I, Karran E, DeStrooper B (2012) The toxic A\u03b2 oligomer and Alzheimer\u2019s disease: an emperor in need of clothes. Nat Neurosci 15(3):349\u2013357. doi:10.1038\/nn.3028","journal-title":"Nat Neurosci"},{"issue":"8","key":"1489_CR9","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1001\/archneurol.2012.90","volume":"69","author":"K Blennow","year":"2012","unstructured":"Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E (2012) Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 69(8):1002\u20131010. doi:10.1001\/archneurol.2012.90","journal-title":"Arch Neurol"},{"issue":"2","key":"1489_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s00401-013-1129-2","volume":"126","author":"Y Bouter","year":"2013","unstructured":"Bouter Y, Dietrich K, Wittnam JL, Rezaei-Ghaleh N, Pillot T, Papot-Couturier S, Lefebvre T, Sprenger F, Wirths O, Zweckstetter M, Bayer TA (2013) N-truncated amyloid \u03b2 (A\u03b2) 4\u201342 forms stable aggregates and induces acute and long-lasting behavioral deficits. Acta Neuropathol 126(2):189\u2013205. doi:10.1007\/s00401-013-1129-2","journal-title":"Acta Neuropathol"},{"issue":"40","key":"1489_CR11","doi-asserted-by":"publisher","first-page":"9096","DOI":"10.1523\/JNEUROSCI.1697-05.2005","volume":"25","author":"M Buttini","year":"2005","unstructured":"Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, Johnson-Wood K, Khan K, Seubert P, Freedman S, Schenk D, Games D (2005) Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer\u2019s disease. J Neurosci 25(40):9096\u20139101. doi:10.1523\/JNEUROSCI.1697-05.2005","journal-title":"J Neurosci"},{"issue":"4","key":"1489_CR12","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/S0002-9440(10)63388-3","volume":"165","author":"C Casas","year":"2004","unstructured":"Casas C, Sergeant N, Itier J, Blanchard V, Wirths O, van der Kolk N, Vingtdeux V, van de Steeg E, Ret G, Canton T, Drobecq H, Clark A, Bonici B, Delacourte A, Benavides J, Schmitz C, Tremp G, Bayer TA, Benoit P, Pradier L (2004) Massive CA1\/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol 165(4):1289\u20131300","journal-title":"Am J Pathol"},{"issue":"6","key":"1489_CR13","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00401-008-0451-6","volume":"116","author":"DZ Christensen","year":"2008","unstructured":"Christensen DZ, Kraus SL, Flohr A, Cotel M, Wirths O, Bayer TA (2008) Transient intraneuronal A beta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP\/PS1KI mice. Acta Neuropathol 116(6):647\u2013655. doi:10.1007\/s00401-008-0451-6","journal-title":"Acta Neuropathol"},{"key":"1489_CR14","doi-asserted-by":"publisher","first-page":"9649","DOI":"10.1038\/srep09649","volume":"5","author":"Gabriela A N Crespi","year":"2015","unstructured":"Crespi Gabriela A N, Hermans SJ, Parker MW, Miles LA (2015) Molecular basis for mid-region amyloid-\u03b2 capture by leading Alzheimer\u2019s disease immunotherapies. Sci Rep 5:9649. doi:10.1038\/srep09649","journal-title":"Sci Rep"},{"issue":"5","key":"1489_CR15","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0197-4580(01)00245-7","volume":"22","author":"P Das","year":"2001","unstructured":"Das P (2001) Reduced effectiveness of A\u00ce21-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging 22(5):721\u2013727. doi:10.1016\/S0197-4580(01)00245-7","journal-title":"Neurobiol Aging"},{"issue":"15","key":"1489_CR16","doi-asserted-by":"publisher","first-page":"8850","DOI":"10.1073\/pnas.151261398","volume":"98","author":"RB DeMattos","year":"2001","unstructured":"DeMattos RB, Bales KR, Cummins DJ, Dodart J, Paul SM, Holtzman DM (2001) Peripheral anti-A\u03b2 antibody alters CNS and plasma A\u03b2 clearance and decreases brain A\u03b2 burden in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci USA 98(15):8850\u20138855. doi:10.1073\/pnas.151261398","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"1489_CR17","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","volume":"76","author":"RB DeMattos","year":"2012","unstructured":"DeMattos RB, Lu J, Tang Y, Racke MM, Delong CA, Tzaferis JA, Hole JT, Forster BM, McDonnell PC, Liu F, Kinley RD, Jordan WH, Hutton ML (2012) A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer\u2019s disease mice. Neuron 76(5):908\u2013920. doi:10.1016\/j.neuron.2012.10.029","journal-title":"Neuron"},{"issue":"5","key":"1489_CR18","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/nn842","volume":"5","author":"J Dodart","year":"2002","unstructured":"Dodart J, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer\u2019s disease model. Nat Neurosci 5(5):452\u2013457. doi:10.1038\/nn842","journal-title":"Nat Neurosci"},{"issue":"4","key":"1489_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 370(4):311\u2013321. doi:10.1056\/NEJMoa1312889","journal-title":"N Engl J Med"},{"issue":"3","key":"1489_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/alzrt261","volume":"6","author":"H Feinberg","year":"2014","unstructured":"Feinberg H, Saldanha JW, Diep L, Goel A, Widom A, Veldman GM, Weis WI, Schenk D, Basi GS (2014) Crystal structure reveals conservation of amyloid-\u03b2 conformation recognized by 3D6 following humanization to bapineuzumab. Alzheimers Res Ther 6(3):31. doi:10.1186\/alzrt261","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"1489_CR21","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1212\/01.WNL.0000159743.08996.99","volume":"64","author":"NC Fox","year":"2005","unstructured":"Fox NC, Black RS, Gilman S, Rossor MN, Griffith SG, Jenkins L, Koller M (2005) Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 64(9):1563\u20131572. doi:10.1212\/01.WNL.0000159743.08996.99","journal-title":"Neurology"},{"issue":"2","key":"1489_CR22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ajpath.2013.05.005","volume":"183","author":"JL Frost","year":"2013","unstructured":"Frost JL, Le KX, Cynis H, Ekpo E, Kleinschmidt M, Palmour RM, Ervin FR, Snigdha S, Cotman CW, Saido TC, Vassar RJ, St George-Hyslop P, Ikezu T, Schilling S, Demuth H, Lemere CA (2013) Pyroglutamate-3 amyloid-beta deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. Am J Pathol 183(2):369\u2013381. doi:10.1016\/j.ajpath.2013.05.005","journal-title":"Am J Pathol"},{"issue":"1\u20134","key":"1489_CR23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1159\/000335913","volume":"10","author":"JL Frost","year":"2012","unstructured":"Frost JL, Liu B, Kleinschmidt M, Schilling S, Demuth H, Lemere CA (2012) Passive immunization against pyroglutamate-3 amyloid-\u03b2 reduces plaque burden in Alzheimer-like transgenic mice: a pilot study. Neurodegener Dis 10(1\u20134):265\u2013270. doi:10.1159\/000335913","journal-title":"Neurodegener Dis"},{"issue":"8","key":"1489_CR24","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nbt0812-731","volume":"30","author":"K Garber","year":"2012","unstructured":"Garber K (2012) Genentech\u2019s Alzheimer\u2019s antibody trial to study disease prevention. Nat Biotechnol 30(8):731\u2013732. doi:10.1038\/nbt0812-731","journal-title":"Nat Biotechnol"},{"issue":"1","key":"1489_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0002-9440(10)64700-1","volume":"156","author":"GK Gouras","year":"2000","unstructured":"Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, Greenfield JP, Haroutunian V, Buxbaum JD, Xu H, Greengard P, Relkin NR (2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol 156(1):15\u201320","journal-title":"Am J Pathol"},{"issue":"23\u201324","key":"1489_CR26","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.lfs.2012.06.004","volume":"91","author":"GK Gouras","year":"2012","unstructured":"Gouras GK, Will\u00e9n K, Tampellini D (2012) Critical role of intraneuronal A\u03b2 in Alzheimer\u2019s disease: technical challenges in studying intracellular A\u03b2. Life Sci 91(23\u201324):1153\u20131158. doi:10.1016\/j.lfs.2012.06.004","journal-title":"Life Sci"},{"issue":"8","key":"1489_CR27","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1073\/pnas.86.8.2853","volume":"86","author":"I Grundke-Iqbal","year":"1989","unstructured":"Grundke-Iqbal I, Iqbal K, George L, Tung YC, Kim KS, Wisniewski HM (1989) Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease. Proc Natl Acad Sci USA 86(8):2853\u20132857","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"1489_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrm2101","volume":"8","author":"C Haass","year":"2007","unstructured":"Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid beta-peptide. Nat Rev Mol Cell Biol 8(2):101\u2013112. doi:10.1038\/nrm2101","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"1489_CR29","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","volume":"12","author":"J Hardy","year":"1991","unstructured":"Hardy J, Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharmacol Sci 12(10):383\u2013388","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"1489_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1586\/eci.11.93","volume":"8","author":"BP Imbimbo","year":"2012","unstructured":"Imbimbo BP, Ottonello S, Frisardi V, Solfrizzi V, Greco A, Seripa D, Pilotto A, Panza F (2012) Solanezumab for the treatment of mild-to-moderate Alzheimer\u2019s disease. Expert Rev Clin Immunol 8(2):135\u2013149. doi:10.1586\/eci.11.93","journal-title":"Expert Rev Clin Immunol"},{"issue":"6815","key":"1489_CR31","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/35050110","volume":"408","author":"C Janus","year":"2000","unstructured":"Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer\u2019s disease. Nature 408(6815):979\u2013982. doi:10.1038\/35050110","journal-title":"Nature"},{"key":"1489_CR32","doi-asserted-by":"publisher","unstructured":"Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O (2010) Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta aggregation in the 5XFAD mouse model of Alzheimer\u2019s disease. Neurobiol Aging. doi:10.1016\/j.neurobiolaging.2010.05.027","DOI":"10.1016\/j.neurobiolaging.2010.05.027"},{"issue":"15","key":"1489_CR33","doi-asserted-by":"crossref","first-page":"6331","DOI":"10.1523\/JNEUROSCI.22-15-06331.2002","volume":"22","author":"LA Kotilinek","year":"2002","unstructured":"Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH (2002) Reversible memory loss in a mouse transgenic model of Alzheimer\u2019s disease. J Neurosci 22(15):6331\u20136335","journal-title":"J Neurosci"},{"issue":"3","key":"1489_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/alzrt258","volume":"6","author":"MP Kummer","year":"2014","unstructured":"Kummer MP, Heneka MT (2014) Truncated and modified amyloid-beta species. Alzheimers Res Ther 6(3):28. doi:10.1186\/alzrt258","journal-title":"Alzheimers Res Ther"},{"issue":"16","key":"1489_CR35","doi-asserted-by":"publisher","first-page":"12991","DOI":"10.1074\/jbc.M007859200","volume":"276","author":"YM Kuo","year":"2001","unstructured":"Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, Kalback WM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Roher AE (2001) Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer\u2019s disease brains. J Biol Chem 276(16):12991\u201312998. doi:10.1074\/jbc.M007859200","journal-title":"J Biol Chem"},{"issue":"2","key":"1489_CR36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/alzrt246","volume":"6","author":"L Lannfelt","year":"2014","unstructured":"Lannfelt L, M\u00f6ller C, Basun H, Osswald G, Sehlin D, Satlin A, Logovinsky V, Gellerfors P (2014) Perspectives on future Alzheimer therapies: amyloid-\u03b2 protofibrils\u2014a new target for immunotherapy with BAN2401 in Alzheimer\u2019s disease. Alzheimers Res Ther 6(2):16. doi:10.1186\/alzrt246","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"1489_CR37","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jmb.2003.11.019","volume":"335","author":"J Legleiter","year":"2004","unstructured":"Legleiter J, Czilli DL, Gitter B, DeMattos RB, Holtzman DM, Kowalewski T (2004) Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. J Mol Biol 335(4):997\u20131006","journal-title":"J Mol Biol"},{"key":"1489_CR38","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1750-1326-8-36","volume":"8","author":"CA Lemere","year":"2013","unstructured":"Lemere CA (2013) Immunotherapy for Alzheimer\u2019s disease: hoops and hurdles. Mol Neurodegener 8:36. doi:10.1186\/1750-1326-8-36","journal-title":"Mol Neurodegener"},{"issue":"Pt 5","key":"1489_CR39","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1093\/brain\/awt062","volume":"136","author":"SE Lesn\u00e9","year":"2013","unstructured":"Lesn\u00e9 SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, Ashe KH (2013) Brain amyloid-\u03b2 oligomers in ageing and Alzheimer\u2019s disease. Brain 136(Pt 5):1383\u20131398. doi:10.1093\/brain\/awt062","journal-title":"Brain"},{"issue":"12","key":"1489_CR40","doi-asserted-by":"publisher","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","volume":"82","author":"CL Masters","year":"1985","unstructured":"Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82(12):4245\u20134249","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"1489_CR41","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/nm790","volume":"8","author":"J McLaurin","year":"2002","unstructured":"McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, French JE, Lambermon MHL, Darabie AA, Brown ME, Janus C, Chishti MA, Horne P, Westaway D, Fraser PE, Mount HTJ, Przybylski M, St George-Hyslop P (2002) Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4\u201310 and inhibit cytotoxicity and fibrillogenesis. Nat Med 8(11):1263\u20131269. doi:10.1038\/nm790","journal-title":"Nat Med"},{"issue":"6","key":"1489_CR42","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M","volume":"46","author":"CA McLean","year":"1999","unstructured":"McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer\u2019s disease. Ann. Neurol 46(6):860\u2013866","journal-title":"Ann. Neurol"},{"key":"1489_CR43","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-142868","author":"JN Meissner","year":"2014","unstructured":"Meissner JN, Bouter Y, Bayer TA (2014) Neuron loss and behavioral deficits in the TBA42 mouse model expressing N-truncated pyroglutamate amyloid-beta3\u201342. J Alzheimers Dis. doi:10.3233\/JAD-142868","journal-title":"J Alzheimers Dis"},{"key":"1489_CR44","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/srep01302","volume":"3","author":"LA Miles","year":"2013","unstructured":"Miles LA, Crespi Gabriela A N, Doughty L, Parker MW (2013) Bapineuzumab captures the N-terminus of the Alzheimer\u2019s disease amyloid-beta peptide in a helical conformation. Sci Rep 3:1302. doi:10.1038\/srep01302","journal-title":"Sci Rep"},{"issue":"10","key":"1489_CR45","doi-asserted-by":"publisher","first-page":"6483","DOI":"10.1074\/jbc.274.10.6483","volume":"274","author":"D Moechars","year":"1999","unstructured":"Moechars D, Dewachter I, Lorent K, Revers\u00e9 D, Baekelandt V, Naidu A, Tesseur I, Spittaels K, Haute CV, Checler F, Godaux E, Cordell B, van Leuven F (1999) Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J Biol Chem 274(10):6483\u20136492","journal-title":"J Biol Chem"},{"issue":"1","key":"1489_CR46","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1742-4933-10-18","volume":"10","author":"J Moreth","year":"2013","unstructured":"Moreth J, Mavoungou C, Schindowski K (2013) Passive anti-amyloid immunotherapy in Alzheimer\u2019s disease: what are the most promising targets? Immun Ageing 10(1):18. doi:10.1186\/1742-4933-10-18","journal-title":"Immun Ageing"},{"issue":"12","key":"1489_CR47","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jama.283.12.1571","volume":"283","author":"J N\u00e4slund","year":"2000","unstructured":"N\u00e4slund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283(12):1571\u20131577","journal-title":"JAMA"},{"issue":"40","key":"1489_CR48","doi-asserted-by":"publisher","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","volume":"26","author":"H Oakley","year":"2006","unstructured":"Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, van Eldik L, Berry R, Vassar R (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer\u2019s disease mutations: potential factors in amyloid plaque formation. J Neurosci 26(40):10129\u201310140. doi:10.1523\/JNEUROSCI.1202-06.2006","journal-title":"J Neurosci"},{"issue":"3","key":"1489_CR49","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","volume":"39","author":"S Oddo","year":"2003","unstructured":"Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer\u2019s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39(3):409\u2013421","journal-title":"Neuron"},{"issue":"1","key":"1489_CR50","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","volume":"61","author":"J Orgogozo","year":"2003","unstructured":"Orgogozo J, Gilman S, Dartigues J, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61(1):46\u201354","journal-title":"Neurology"},{"issue":"2","key":"1489_CR51","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/YCO.0000000000000041","volume":"27","author":"F Panza","year":"2014","unstructured":"Panza F, Logroscino G, Imbimbo BP, Solfrizzi V (2014) Is there still any hope for amyloid-based immunotherapy for Alzheimer\u2019s disease? Curr Opin Psychiatry 27(2):128\u2013137. doi:10.1097\/YCO.0000000000000041","journal-title":"Curr Opin Psychiatry"},{"issue":"41","key":"1489_CR52","doi-asserted-by":"publisher","first-page":"23895","DOI":"10.1074\/jbc.270.41.23895","volume":"270","author":"CJ Pike","year":"1995","unstructured":"Pike CJ, Overman MJ, Cotman CW (1995) Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem 270(41):23895\u201323898","journal-title":"J Biol Chem"},{"issue":"6","key":"1489_CR53","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.biocel.2008.12.015","volume":"41","author":"SW Pimplikar","year":"2009","unstructured":"Pimplikar SW (2009) Reassessing the amyloid cascade hypothesis of Alzheimer\u2019s disease. Int J Biochem Cell Biol 41(6):1261\u20131268. doi:10.1016\/j.biocel.2008.12.015","journal-title":"Int J Biochem Cell Biol"},{"issue":"3","key":"1489_CR54","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X","volume":"45","author":"JL Price","year":"1999","unstructured":"Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and \u201cpreclinical\u201d Alzheimer\u2019s disease. Ann Neurol 45(3):358\u2013368","journal-title":"Ann Neurol"},{"issue":"6","key":"1489_CR55","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/alzrt220","volume":"5","author":"ND Prins","year":"2013","unstructured":"Prins ND, Scheltens P (2013) Treating Alzheimer\u2019s disease with monoclonal antibodies: current status and outlook for the future. Alzheimers Res Ther 5(6):56. doi:10.1186\/alzrt220","journal-title":"Alzheimers Res Ther"},{"key":"1489_CR56","first-page":"143","volume":"39","author":"R Ravid","year":"1993","unstructured":"Ravid R, Swaab DF (1993) The Netherlands brain bank\u2014a clinico-pathological link in aging and dementia research. J Neural Transm Suppl 39:143\u2013153","journal-title":"J Neural Transm Suppl"},{"issue":"9","key":"1489_CR57","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1176\/ajp.139.9.1136","volume":"139","author":"B Reisberg","year":"1982","unstructured":"Reisberg B, Ferris SH, de Leon MJ, Crook T (1982) The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 139(9):1136\u20131139","journal-title":"Am J Psychiatry"},{"key":"1489_CR58","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-143120","author":"BC Richard","year":"2015","unstructured":"Richard BC, Kurdakova A, Baches S, Bayer TA, Weggen S, Wirths O (2015) Gene dosage dependent aggravation of the neurological phenotype in the 5XFAD Mouse Model of Alzheimer\u2019s disease. J Alzheimers Dis. doi:10.3233\/JAD-143120","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"1489_CR59","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","volume":"9","author":"JO Rinne","year":"2010","unstructured":"Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, Rodriguez Martinez de Liano S, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M (2010) 11C-PiB PET assessment of change in fibrillar amyloid-\u03b2 load in patients with Alzheimer\u2019s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9(4):363\u2013372. doi:10.1016\/S1474-4422(10)70043-0","journal-title":"Lancet Neurol"},{"issue":"4","key":"1489_CR60","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 370(4):322\u2013333. doi:10.1056\/NEJMoa1304839","journal-title":"N Engl J Med"},{"issue":"6740","key":"1489_CR61","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400(6740):173\u2013177. doi:10.1038\/22124","journal-title":"Nature"},{"issue":"4","key":"1489_CR62","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/S0002-9440(10)63235-X","volume":"164","author":"C Schmitz","year":"2004","unstructured":"Schmitz C, Rutten BPF, Pielen A, Sch\u00e4fer S, Wirths O, Tremp G, Czech C, Blanchard V, Multhaup G, Rezaie P, Korr H, Steinbusch HWM, Pradier L, Bayer TA (2004) Hippocampal neuron loss exceeds amyloid plaque load in a transgenic mouse model of Alzheimer\u2019s disease. Am J Pathol 164(4):1495\u20131502. doi:10.1016\/S0002-9440(10)63235-X","journal-title":"Am J Pathol"},{"issue":"9","key":"1489_CR63","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/nm.2460","volume":"17","author":"DJ Selkoe","year":"2011","unstructured":"Selkoe DJ (2011) Resolving controversies on the path to Alzheimer\u2019s therapeutics. Nat Med 17(9):1060\u20131065. doi:10.1038\/nm.2460","journal-title":"Nat Med"},{"issue":"6","key":"1489_CR64","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1046\/j.1471-4159.2003.01818.x","volume":"85","author":"N Sergeant","year":"2003","unstructured":"Sergeant N, Bombois S, Ghestem A, Drobecq H, Kostanjevecki V, Missiaen C, Wattez A, David J, Vanmechelen E, Sergheraert C, Delacourte A (2003) Truncated beta-amyloid peptide species in pre-clinical Alzheimer\u2019s disease as new targets for the vaccination approach. J Neurochem 85(6):1581\u20131591","journal-title":"J Neurochem"},{"issue":"2","key":"1489_CR65","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000112834","volume":"5","author":"P Seubert","year":"2008","unstructured":"Seubert P, Barbour R, Khan K, Motter R, Tang P, Kholodenko D, Kling K, Schenk D, Johnson-Wood K, Schroeter S, Gill D, Jacobsen JS, Pangalos M, Basi G, Games D (2008) Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. Neurodegener Dis 5(2):65\u201371. doi:10.1159\/000112834","journal-title":"Neurodegener Dis"},{"issue":"8","key":"1489_CR66","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1073\/pnas.94.8.4109","volume":"94","author":"B Solomon","year":"1997","unstructured":"Solomon B, Koppel R, Frankel D, Hanan-Aharon E (1997) Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA 94(8):4109\u20134112","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1489_CR67","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1073\/pnas.93.1.452","volume":"93","author":"B Solomon","year":"1996","unstructured":"Solomon B, Koppel R, Hanan E, Katzav T (1996) Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci USA 93(1):452\u2013455","journal-title":"Proc Natl Acad Sci USA"},{"key":"1489_CR68","doi-asserted-by":"publisher","unstructured":"Spencer B, Masliah E (2014) Immunotherapy for Alzheimer\u2019s disease: past, present and future. Front Aging Neurosci 6. doi:10.3389\/fnagi.2014.00114","DOI":"10.3389\/fnagi.2014.00114"},{"issue":"3","key":"1489_CR69","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","volume":"11","author":"R Sperling","year":"2012","unstructured":"Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M (2012) Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 11(3):241\u2013249. doi:10.1016\/S1474-4422(12)70015-7","journal-title":"Lancet Neurol"},{"issue":"5","key":"1489_CR70","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/S0002-9440(10)64463-X","volume":"161","author":"RH Takahashi","year":"2002","unstructured":"Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greengard P, Gouras GK (2002) Intraneuronal Alzheimer Abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161(5):1869\u20131879","journal-title":"Am J Pathol"},{"key":"1489_CR71","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-014-1290-2","author":"AD Watt","year":"2014","unstructured":"Watt AD, Crespi Gabriela A N, Down RA, Ascher DB, Gunn A, Perez KA, McLean CA, Villemagne VL, Parker MW, Barnham KJ, Miles LA (2014) Do current therapeutic anti-A\u03b2 antibodies for Alzheimer\u2019s disease engage the target? Acta Neuropathol. doi:10.1007\/s00401-014-1290-2","journal-title":"Acta Neuropathol"},{"issue":"11","key":"1489_CR72","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1089\/10445490152717596","volume":"20","author":"DM Wilcock","year":"2001","unstructured":"Wilcock DM, Gordon MN, Ugen KE, Gottschall PE, DiCarlo G, Dickey C, Boyett KW, Jantzen PT, Connor KE, Melachrino J, Hardy J, Morgan D (2001) Number of Abeta inoculations in APP\u00a0+\u00a0PS1 transgenic mice influences antibody titers, microglial activation, and congophilic plaque levels. DNA Cell Biol 20(11):731\u2013736. doi:10.1089\/10445490152717596","journal-title":"DNA Cell Biol"},{"issue":"1","key":"1489_CR73","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00702-009-0314-x","volume":"117","author":"O Wirths","year":"2010","unstructured":"Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, Kalimo H, Lannfelt L, Bayer TA (2010) Pyroglutamate Abeta pathology in APP\/PS1KI mice, sporadic and familial Alzheimer\u2019s disease cases. J Neural Transm 117(1):85\u201396. doi:10.1007\/s00702-009-0314-x","journal-title":"J Neural Transm"},{"issue":"4","key":"1489_CR74","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00401-009-0557-5","volume":"118","author":"O Wirths","year":"2009","unstructured":"Wirths O, Breyhan H, Cynis H, Schilling S, Demuth H, Bayer TA (2009) Intraneuronal pyroglutamate-Abeta 3\u201342 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol 118(4):487\u2013496. doi:10.1007\/s00401-009-0557-5","journal-title":"Acta Neuropathol"},{"issue":"53","key":"1489_CR75","doi-asserted-by":"publisher","first-page":"41517","DOI":"10.1074\/jbc.M110.178707","volume":"285","author":"O Wirths","year":"2010","unstructured":"Wirths O, Erck C, Martens H, Harmeier A, Geumann C, Jawhar S, Kumar S, Multhaup G, Walter J, Ingelsson M, Degerman-Gunnarsson M, Kalimo H, Huitinga I, Lannfelt L, Bayer TA (2010) Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis. J Biol Chem 285(53):41517\u201341524. doi:10.1074\/jbc.M110.178707","journal-title":"J Biol Chem"},{"issue":"4","key":"1489_CR76","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.bcp.2013.12.020","volume":"88","author":"T Wisniewski","year":"2014","unstructured":"Wisniewski T, Go\u00f1i F (2014) Immunotherapy for Alzheimer\u2019s disease. Biochem Pharmacol 88(4):499\u2013507. doi:10.1016\/j.bcp.2013.12.020","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"1489_CR77","doi-asserted-by":"publisher","first-page":"8154","DOI":"10.1074\/jbc.M111.308601","volume":"287","author":"JL Wittnam","year":"2012","unstructured":"Wittnam JL, Portelius E, Zetterberg H, Gustavsson MK, Schilling S, Koch B, Demuth H, Blennow K, Wirths O, Bayer TA (2012) Pyroglutamate amyloid \u03b2 (A\u03b2) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease. J Biol Chem 287(11):8154\u20138162. doi:10.1074\/jbc.M111.308601","journal-title":"J Biol Chem"},{"issue":"8","key":"1489_CR78","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1523\/JNEUROSCI.1676-11.2012","volume":"32","author":"W Zago","year":"2012","unstructured":"Zago W, Buttini M, Comery TA, Nishioka C, Gardai SJ, Seubert P, Games D, Bard F, Schenk D, Kinney GG (2012) Neutralization of soluble, synaptotoxic amyloid beta species by antibodies is epitope specific. J Neurosci 32(8):2696\u20132702. doi:10.1523\/JNEUROSCI.1676-11.2012","journal-title":"J Neurosci"}],"updated-by":[{"DOI":"10.1007\/s00401-024-02718-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T00:00:00Z","timestamp":1711324800000}}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-015-1489-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00401-015-1489-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-015-1489-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-015-1489-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T06:08:26Z","timestamp":1711346906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00401-015-1489-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,14]]},"references-count":78,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["1489"],"URL":"https:\/\/doi.org\/10.1007\/s00401-015-1489-x","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00401-024-02718-w","asserted-by":"object"}]},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,14]]},"assertion":[{"value":"1 July 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00401-024-02718-w","URL":"https:\/\/doi.org\/10.1007\/s00401-024-02718-w","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A patent application for the antibody NT4X was filed by the University Medicine of Goettingen and Thomas A. Bayer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}